gilead sciences hiv - Search News

HIV, Lenacapavir and Gilead Sciences

Times Now on MSN · 3h

HIV Protection in One Injection? Gilead’s Lenacapavir Could Be a Game-Changer!

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations.

Markets Insider · 2d

Gilead presents data for once-yearly lenacapavir for HIV prevention

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of

The Business Journals · 1d

Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Joplin Globe · 2d

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).

Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a

1d

Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Fierce Pharma2d

A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

2hon MSN

Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

1d

Gilead Presents New HIV Treatment And Cure Research Data

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

10d

Gilead Sciences sets aside $200 million to resolve HIV drug probe

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The Financial Express1d

Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Managed Healthcare Executive6h

If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

BioPharma Dive1d

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

News-Medical.Net on MSN1d

Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Applied Clinical Trials Online4h

Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

2don MSN

HIV prevention medication ‘could one day be a yearly jab’ – study suggests

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results